---
title: Genes affect medication side effects
nct_id: NCT06329739
status: RECRUITING
sponsor: "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico"
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06329739"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06329739"
last_fetched: "2026-05-10T14:04:30.016Z"
source: "Parkinson's Pathways (curated)"
---
# Genes affect medication side effects

**Goal (in five words):** Genes affect medication side effects

**Official Title:** Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes in Patients Undergoing Dopaminergic Treatment

**Trial ID:** [NCT06329739](https://clinicaltrials.gov/study/NCT06329739)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- **Target Enrollment:** 68 participants
- **Start Date:** 2021-12-14
- **Completion Date:** 2031-12-14
- **Conditions:** Parkinson Disease
- **Interventions:** Clinical examinations and clinical scales administration
- **Intervention Types:** DIAGNOSTIC_TEST

## Summary For Families

The goal is to find out whether inherited genetic differences influence thinking, mood, and behavior in people with Parkinson's who are taking dopaminergic medications. Participants who have had genetic testing for Mendelian forms of Parkinson's get detailed clinical exams and standardized cognitive and behavioral scales, and researchers compare those outcomes by genetic status; levodopa and dopamine agonists boost brain dopamine to improve movement but can also cause hallucinations, sleep and memory changes, and impulse control problems, so the study looks at whether genetics affects those effects. Adults 18 and older with a Parkinson's diagnosis who are on levodopa and/or dopamine agonists and have undergone genetic testing are eligible, deep brain stimulation recipients are excluded, and participants must be able to give informed consent.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* diagnosed with Parkinson's Disease (PD)
* in use of dopaminergic medication (L-Dopa and/or dopamine agonists)
* genetic testing for mendelian forms of PD
* able to provide informed consent to participate in the study

Exclusion Criteria:

* Patients underwent Deep Brain Stimulation (DBS) treatment
```

## Locations (1)

- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy _(45.4643, 9.1895)_
  - Francesca Mameli — (CONTACT) — 0255033621 — francesca.mameli@policlinico.mi.it

## Central Contacts

- Francesca Mameli, Dr — (CONTACT) — 0255033621 — francesca.mameli@policlinico.mi.it
- Fabiana Ruggiero, Dr — (CONTACT) — 0255033621 — fabiana.ruggiero@policlinico.mi.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT06329739*  
*HTML version: https://parkinsonspathways.com/trial/NCT06329739*  
*Source data: https://clinicaltrials.gov/study/NCT06329739*